Introduction/Background Implementing the Enhanced Recovery After Surgery (ERAS) protocol in ovarian cancer surgery is essential for improving patient outcomes and minimizing complications. However, applying the ERAS guidelines to these patients can be challenging due to the complexity of cytoreductive surgery, variations in patients‘ nutritional status, and the necessity of collaboration among multidisciplinary team. This study seeks to investigate morbidity outcomes following radical surgery in ovarian cancer patients after the implementation of ERAS protocol.

Methodology This retrospective observational study, conducted at a single institution, included 56 patients. Comprehensive documentation concerning each element within the ERAS protocol and postoperative morbidity was realised for every patient in the study cohort.

Results The sample had an average age of 62 years (±4 years). Most patients were at FIGO stage III (21.1%). Compliance with the ERAS protocol was highest during surgery (85.7%), followed by the postoperative period (75%), and lowest preoperatively (60.7%). The average hospital stay was 4.6 days, with nine readmissions (16%) within 30 days post-surgery. Forty-eight (85.7%) of the patients received chemotherapy within 30 days after surgery.

Conclusion Implementation of the ERAS protocol for ovarian cancer patients undergoing surgery is of paramount importance, primarily due to the imperative of reducing complications in this patient cohort. Additionally, adopting the ERAS pathway not only serves to minimize the average hospital stay but also facilitates the timely initiation of post-surgery chemotherapy, a critical factor contributing to the overall survival of these patients.

Disclosures No comflict of interest.